|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Thyroid crisis显示文摘 | Gavin LA | 1991 | Med Clin North Am1991，75，： | 1 |
| 2 | Treatment alliance and its association with family functioning,adherence,and medical outcome in adolescents with severe,chronic asthma显示文摘 | Gavin LA Wamboldt MZ Sorokin N | 1999 | J Pediatr Psychol1999，24，4： | 1 |
| 3 | The Mechanism of Impaired T3 Production from T4 in Diabetes显示文摘 | Gavin LA McMahon FA Moeller M | 1981 | Diabetes1981，30，8： | 1 |
| 4 | Prevention and treatment of foot problems in diabetes mellitus:a comprehensive program显示文摘 | Gavin LA Stess RM Goldstone J | 1993 | West J Med1993，158，1： | 1 |
| 5 | Prevention and treatment of foot problems in diabetes mellitus: a comprehensive program显示文摘 | Gavin LA Stess RM Goldstone J | 1993 | West J Med1993，158，： | 1 |
| 6 | Prevention and treatment of foot problems in diabetes mellitus:A comprehensive program显示文摘 | Gavin LA Stress RM Goldstone J | | 0，，01： | 1 |
| 7 | Parental criticism and treatment outcome in adolescents hospitalized for severe,chronic asthma显示文摘 | Wamboldt FS Wamboldt MZ Gavin LA | 1995 | Journal of Psychosomatic Research1995，39，8： | 1 |
| 8 | Prevention and treatment of foot problems in diabetes mellitus:A comprehensive program显示文摘 | Gavin LA Stress RM Goldstone J | 1993 | West J Med1993，158，1： | 1 |
| 9 | Pre vention and treatment of foot problems in diabetes mellitus: A comprehensive program显示文摘 | Gavin LA Stess RM Ooldstone J | 1993 | West J Med1993，158，1： | 1 |
| 10 | 利用生物信息学方法和多抗原表位DNA免疫方法研制有效的抗蛇毒血清显示文摘传统的抗蛇毒血清是从全毒免疫的马或绵羊的血清中提取,但目前的免疫方法包括对马或绵羊进行的超免也不能达到对大多数临床上重要的毒素都产生免疫应答的目标。目前利物浦大学的Simon. C. Wagstaff等研究人员开发了一种最新的研制抗蛇毒血清的方法—通过鉴定蛇毒金属蛋白酶(SVMPs,SVMPs主要是产生持续性致死性出血,SVMPs很复杂,它具有多种功能型,能作用于多种底物)中有重要临床意义的7个部分,并将它们改造成单链DNA作为免疫原免疫小鼠产生特异抗体。为研发更合理的抗蛇毒血清制备方法提供了依据。 | 余方芳 范泉水 蓝海 Simon C. Wagstaff Gavin D. Laing R.David G.Theakston Christina Papaspyridis Robert A. Harrison | 2007 | 蛇志2007，19，3： | 0 |
| 11 | Malignancy and mortality in a population-based cohort of patients with coeliac disease or ‘gluten sensitivity’显示文摘AIM: To determine the risk of malignancy and mortality in patients with a positive endomysial or anti-gliadin an- tibody test in Northern Ireland. METHODS: A population-based retrospective cohort study design was used. Laboratory test results used in the diagnosis of coeliac disease were obtained from the Regional Immunology Laboratory, cancer statistics from the Northern Ireland Cancer Registry and mortal- ity statistics from the General Registrar Office, Northern Ireland. Age standardized incidence ratios of malignant neoplasms and standardized mortality ratios of all-cause and cause-specific mortality were calculated. RESULTS: A total of 13 338 people had an endomysial antibody and/or an anti-gliadin antibody test in Northern Ireland between 1993 and 1996. There were 490 pa- tients who tested positive for endomysial antibodies and they were assumed to have coeliac disease. There were 1133 patients who tested positive for anti-gliadin anti- bodies and they were defined as gluten sensitive. Ma- lignant neoplasms were not significantly associated with coeliac disease; however, all-cause mortality was signifi- cantly increased following diagnosis. The standardized incidence and mortality ratios for non-Hodgkin’s lym- phoma were increased in coeliac disease patients but did not reach statistical significance. Lung and breast cancer incidence were significantly lower and all-cause mortal-ity, mortality from malignant neoplasms, non-Hodgkin’s lymphoma and digestive system disorders were signifi- cantly higher in gluten sensitive patients compared to the Northern Ireland population. CONCLUSION: Patients with coeliac disease or gluten sensitivity had higher mortality rates than the Northern Ireland population. This association persists more than one year after diagnosis in patients testing positive for anti-gliadin antibodies. Breast cancer is significantly re- duced in the cohort of patients with gluten sensitivity. | LA Anderson SA McMillan RGP Watson P Monaghan AT Gavin C Fox LJ Murray | 2007 | World Journal of Gastroenterology2007，13，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员